Testosterone 2% gel (Testavan®, Testarzon®) in adult male hypogonadism: a profile of its use
Author:
- 10 April 2019
- journal article
- research article
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 35 (5) , 209-218
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2018
- Efficacy and Safety of a New Topical Testosterone Replacement Gel Therapy for the Treatment of Male HypogonadismEndocrine Practice, 2017
- Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studiesAndrologia, 2017
- The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studiesAndrologia, 2015
- Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guidelineCanadian Medical Association Journal, 2015
- Comparative Safety of Testosterone Dosage FormsJAMA Internal Medicine, 2015
- Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy menClinical Pharmacology in Drug Development, 2014
- Hypogonadism in the Aging Male Diagnosis, Potential Benefits, and Risks of Testosterone Replacement TherapyInternational Journal of Endocrinology, 2012
- Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug deliveryExpert Opinion on Drug Delivery, 2005
- Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosteroneEuropean Journal of Drug Metabolism and Pharmacokinetics, 1986